Microcap Ledger Estrella Immunopharma, Inc. $ESLA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Emeryville, CA
- Fiscal year end
- December 31
- Shares outstanding
- 43,497,864 [10-Q 2026-08-13]
What the company doesAI summary of filing
Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies for cancer and autoimmune diseases. The company's lead program, EB103, is a CD19-directed T-cell therapy currently in Phase I/II clinical trials for relapsed or refractory B-cell non-Hodgkin's lymphomas, with Phase I data showing a 100% complete response rate in the high-dose cohort. The company is pre-revenue and operates by licensing the proprietary ARTEMIS T-cell receptor platform from Eureka Therapeutics, paying milestone and royalty payments upon achievement of development and sales targets. Estrella is advancing a pipeline that includes EB104 for dual CD19/CD22 targeting, exploration of EB103 with an oncolytic virus for solid tumors, and preclinical programs in autoimmune diseases. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$4.60M | −$8.48M | $100.0K | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$13.06M | −$1.79M | $1.38M | [10-K 2026-03-18] |
| FY ended Jun 2024 | — | −$7.31M | −$16.07M | $4.17M | [10-KT 2025-03-25] |
- Quarterly cash burn
- −$4.24M
- Cash runway Estimate
- ~0.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 36,179,147 | [10-Q 2024-11-14] |
| 2025-03-20 | 36,165,589 | [10-KT 2025-03-25] |
| 2025-05-13 | 36,165,589 | [10-Q 2025-05-14] |
| 2025-08-06 | 37,065,589 | [10-Q 2025-08-12] |
| 2025-11-10 | 37,765,589 | [10-Q 2025-11-12] |
| 2026-03-12 | 42,665,228 | [10-K/A 2026-04-30] |
| 2026-05-11 | 43,034,228 | [10-Q 2026-05-18] |
| 2026-08-11 | 43,497,864 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2025-12-22; declared effective 2026-01-23 [S-1 2025-12-22]
Listing status
Current status: 6 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-08. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-08] |
| 2026-08-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-21] |
| 2026-01-13 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-13] |
| 2025-08-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-07] |
| 2025-05-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-02] |
| 2024-11-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-25] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-25 | Liu Cheng | exercise | 100,000 | $0.81 | [4 2026-08-26] |
| 2026-08-18 | Xu Jiandong | exercise | 100,000 | $0.81 | [4 2026-08-25] |
| 2025-10-07 | Xu Jiandong | buy | 1,000 | $1.33 | [4 2026-04-29] |
| 2025-09-22 | Xu Jiandong | buy | 1,000 | $1.16 | [4 2026-04-29] |
| 2025-09-11 | Xu Jiandong | buy | 100 | $1.04 | [4 2026-04-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-08 | 8-K | Listing notice or transfer |
| 2026-08-21 | 8-K | Listing notice or transfer |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-06-30 | 8-K | Shareholder vote results |
| 2026-05-27 | DEF 14A | Proxy statement |
| 2026-05-18 | 10-Q | Quarterly report |
| 2026-05-18 | NT 10-Q | Notice of late quarterly report |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-04-30 | 10-K/A | Amended report |
| 2026-03-18 | 10-K | Annual report |
| 2026-02-13 | 424B3 | Prospectus or prospectus supplement |
Alerts for $ESLA
Email me when Estrella Immunopharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.